Comparing GoodRx (NASDAQ:GDRX) & Q Biomed (OTCMKTS:QBIO)

Q Biomed (OTCMKTS:QBIO) and GoodRx (NASDAQ:GDRX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares Q Biomed and GoodRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
GoodRx	3.97%	9.73%	4.79%

Risk and Volatility

Q Biomed has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Q Biomed and GoodRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
GoodRx	2	6	6	0	2.29

GoodRx has a consensus price target of $5.15, suggesting a potential upside of 91.29%. Given GoodRx’s stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than Q Biomed.

Insider & Institutional Ownership

63.8% of GoodRx shares are owned by institutional investors. 28.2% of Q Biomed shares are owned by company insiders. Comparatively, 4.2% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Q Biomed and GoodRx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	$0.08	0.00
GoodRx	$800.65 million	1.14	$16.39 million	$0.09	29.89

GoodRx has higher revenue and earnings than Q Biomed. Q Biomed is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Summary

GoodRx beats Q Biomed on 10 of the 12 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.